# Can-Fite BioPharma Ltd. (CANF)

Source page: https://stoqly.net/companies/canf

- **Ticker:** CANF (NYSE)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001536196
- **Latest annual report:** 20-F filed 2026-03-26 (https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/ea0282586-20f_canfite.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $1.62 on 2026-10-30
- **Market cap:** $1.3M
- **EPS, trailing 12 months:** −$11.94
- **Revenue (FY2025):** $0.4M
- **Revenue growth:** −39.9%
- **Revenue growth, 5-year CAGR:** −11.9%
- **Operating margin:** −2,456.8%
- **Net margin:** −2,426.7%
- **Free cash flow:** −$9.0M
- **Free cash flow margin:** −2,210.1%
- **Return on equity:** −178.2%
- **Change in share count:** +126.9%
- **Piotroski F-score:** 1/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/canf/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | — | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| Operating income | — | -7 | -5 | -12 | -14 | -13 | -10 | -8 | -8 | -10 |
| Net income | -8 | -5 | -7 | -13 | -14 | -13 | -10 | -8 | -8 | -10 |
| Diluted EPS (US$) | — | -0.28 | -0.34 | -0.28 | -0.08 | -0.06 | -0.02 | -35.84 | -21.72 | -11.94 |
| Operating cash flow | — | -9 | -4 | -11 | -12 | -10 | -11 | -8 | -8 | -9 |
| Free cash flow | — | -9 | -4 | -11 | -12 | -10 | -11 | -8 | -8 | -9 |
| Cash | 8 | 4 | 4 | 3 | 8 | 5 | 3 | 4 | 5 | 6 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.